Research Analysts Issue Forecasts for Indivior Q3 Earnings

Key Points

• HC Wainwright analysts expect Indivior PLC to report $0.33 per share earnings in Q3 2025, with an overall full-year estimate of $1.22 EPS.
• Recent earnings results showed that Indivior exceeded estimates with $0.51 EPS and revenue of $302 million, beating expectations of $239.43 million.
• The stock has a consensus rating of "Buy" and an average target price of $19.60, with significant institutional interest reflected in recent increases in holdings from multiple major investors.

Indivior PLC (NASDAQ:INDV - Free Report) - Research analysts at HC Wainwright issued their Q3 2025 EPS estimates for Indivior in a report issued on Wednesday, August 6th. HC Wainwright analyst B. Folkes forecasts that the company will post earnings of $0.33 per share for the quarter. HC Wainwright has a "Buy" rating and a $27.00 price target on the stock. The consensus estimate for Indivior's current full-year earnings is $1.22 per share. HC Wainwright also issued estimates for Indivior's Q4 2025 earnings at $0.35 EPS, FY2025 earnings at $1.64 EPS, FY2026 earnings at $1.90 EPS, FY2027 earnings at $1.97 EPS, FY2028 earnings at $2.09 EPS and FY2029 earnings at $2.29 EPS.

Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.26 by $0.25. The firm had revenue of $302.00 million during the quarter, compared to the consensus estimate of $239.43 million. Indivior had a net margin of 6.65% and a negative return on equity of 86.28%.

Several other equities analysts have also recently issued reports on the stock. Craig Hallum boosted their price target on shares of Indivior from $15.00 to $22.00 and gave the company a "buy" rating in a research report on Monday, June 30th. Jefferies Financial Group began coverage on shares of Indivior in a research report on Tuesday, July 22nd. They set a "buy" rating and a $20.00 price objective on the stock. Finally, Wall Street Zen raised shares of Indivior from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $19.60.

Indivior Stock Performance

Shares of NASDAQ:INDV traded up $0.71 during midday trading on Friday, hitting $23.00. 1,805,915 shares of the stock traded hands, compared to its average volume of 1,793,515. Indivior has a one year low of $7.33 and a one year high of $23.16. The business's 50 day moving average is $16.02 and its two-hundred day moving average is $12.32.

Hedge Funds Weigh In On Indivior

Institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. purchased a new position in Indivior during the fourth quarter valued at $36,000. Lazard Asset Management LLC purchased a new position in shares of Indivior in the 4th quarter worth $57,000. Amalgamated Bank purchased a new position in shares of Indivior in the 2nd quarter worth $61,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Indivior by 16.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company's stock worth $71,000 after buying an additional 666 shares in the last quarter. Finally, Schaper Benz & Wise Investment Counsel Inc. WI purchased a new position in shares of Indivior in the 1st quarter worth $95,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.